DeepCure Inc.


STEX25
Active dates:

October 14, 2021 - October 14, 2021
STEX25 Participation:
October 14, 2021 - November 3, 2022
Company information
Elevator Pitch

Elevator Pitch

DeepCure, founded by researchers from the MIT Media Lab, develops disruptive Artificial Intelligence technology to revolutionize pharmaceutical development. DeepCure is transforming the field of small-molecule drug discovery, by delivering better drugs in a faster and cheaper way.
Description

Description

DeepCure develops disruptive Artificial Intelligence technology to revolutionize pharmaceutical development. The pharma industry is undoubtedly one of the world's largest, with worldwide revenues topping one trillion US dollars. However, its effectiveness is in question, as the exponentially increasing cost of drug discovery and development has resulted in fewer new drugs reaching patients at a much higher price. At the origin of this problem, lies our inability to exhaustively search the astronomical drug-like molecules space for an efficacious drug to a disease-related biological target. To enable future development and reverse the decaying trend, we need a paradigm shift in the form of efficient exploration methods.

DeepCure's AI algorithms analyze a trillion drug candidates from the proprietary virtual library and accurately point out the most promising ones while accounting for the dynamic nature of the target and optimizing the required ADMET properties. DeepCure's AI helps identify novel optimization steps that would escape the eyes of even the most experienced medicinal chemist. These steps improve the success rates of drug candidates in subsequent development stages while reducing time and cost. Innovative generative modeling and reinforcement learning methods enable a breakthrough in CADD - Rational Machine Design, a combination of the rational intuition of human chemists with the abstraction abilities and compute power of Artificial Intelligence.
Technology Description

Technology Description

The experienced scientists and engineers optimize all phases of drug-discovery, including early hit identification, hit-to-lead, lead optimization, patent strategy, and preparation for IND filing, yielding shorter timelines to develop the highest-quality drug candidates.

DeepCure is using AI-driven drug discovery to ensure better molecules and faster cures. The mission is to discover, develop and deliver to patients novel, small molecule drugs that were previously undruggable or undiscovered until our technology came along.